Artificial intelligence (AI) continues to entice. On the exhibition floor at the 2023 Congress of the European Academy of Neurology, one company’s booth featured “Mindart” technology. A passersby could answer a short series of prompts, and get a unique image based on the input made by generative AI. Entertainment aside, medically speaking, AI applications “are still research,” Riccardo Soffietti told his audience at one of several sessions devoted to AI. “But obviously, research is the future.”
New and updated clinical data presented by biopharma firms at the European Association for the Study of the Liver Congress, including: 89bio, Arrowhead, Mirum, Takeda, Vir.
New and updated clinical data presented by biopharma firms at the American Diabetes Association's 83rd Scientific Sessions, including: Biomea, Carmot, Eli Lilly, Inversago, Novo, Sernova, Vertex, Zealand.
As earlier-stage efforts in oncology continue with BMF-219, Biomea Fusion Inc. rolled out new clinical data June 23 from the first two cohorts of patients with type 2 diabetes enrolled in the phase II part of its ongoing phase I/II study called Covalent-111 testing the same compound, an oral covalent menin inhibitor.
Curocell Inc. is inching closer to realizing Korea’s first domestically developed CAR T therapy, presenting “encouraging” interim phase II trial results for anbalcabtagene-autoleucel at the International Conference on Malignant Lymphoma in Lugano, Switzerland.
New and updated preclinical and clinical data presented by biopharma firms at the European Hematology Association Congress, including: Actinium, Aptose, Cellectis, Disc, Geron, Gracell, Humanigen, Innate, Innovent, Kura, Modus, Nkarta, Salarius, Sumitomo.
Disc Medicine Inc.’s positive phase II data from an ongoing, open-label trial called Beacon with oral bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) whetted investor appetite for the results of the other mid-stage Disc experiment known as Aurora with the compound, due early next year.
Barring truly major surprises, exagamglogene autotemcel (Exa-cel, Vertex Pharmaceuticals Inc.) is on track to become the first approved CRISPR-based gene editing therapy. It is partly in expectation of Exa-cel’s approval that the European Hematology Association (EHA) and the European Society for Bone Marrow Transplantation hosted a session on “transplantation versus gene therapy in sickle cell disease.”
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Amgen, Ascentage, Beyondspring, Bicara, Cohbar, Immvira, Jazz, Kite, Merck & Co., Moderna, Morphogenesis, Nascent, Neximmune, Nkgen, Oncoinvent, Oncolytics, Portage, Precigen, Promontory, Puma, Replimune, Servier, Sorrento, Sutro, Zentalis, Zymeworks.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Agenus, Akeso, Alligator, Arcus, Atara, Bold, Coherus, Dragonfly, Ellipses, Erasca, Fulgent Genetics, Galera, Gilead, Gilead Sciences, Gracell, Iaso, Immunocore, Immunogen, Immutep, Innovent Biologics, Intensity, ISA, Janssen, Kite, Linnaeus, Memgen, NEC, Precigen, Transcenta, Transgene.
RSS
